Review of Liraglutide versus Sitagliptin for Patients with Uncontrolled Type 2 Diabetes: More Effective HbA_1c Reduction with Subcutaneous GLP-1 Receptor Agonist Versus an Oral DPP-4 Inhibitor

References

• . Eeg-Olofsson K, Cederholm J, Nilsson PM, . Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65–73
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929–2940
   PubMed Web of Science ®Google Scholar
• . Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 suppl):S3–S10
   Google Scholar
• . Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6 suppl):S37–S50
   PubMed Web of Science ®Google Scholar
• . Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053
   PubMed Web of Science ®Google Scholar
• . Mokdad AH, Ford ES, Bowman BA, . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):837–853
   Google Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Miller ME, Byington RP; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . Patel A, MacMahon S, Chalmers J, ; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Buse JB, Ginsberg HN, Bakris GL, ; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–172
   PubMed Web of Science ®Google Scholar
• . Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s. The Framingham Heart Study. Circulation. 2006;113(25):2914–2918
   PubMed Web of Science ®Google Scholar
• . Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care. 2008;31(8):1582–1584
   PubMed Web of Science ®Google Scholar
• . Pi-Sunyer X, Blackburn G, Brancati FL, Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383
   PubMed Web of Science ®Google Scholar
• . Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 1999;48(4):839–847
   PubMed Web of Science ®Google Scholar
• . Weyer C, Hanson K, Bogardus C, Pratley RE. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia. 2000;43(1):36–46
   PubMed Web of Science ®Google Scholar
• . Ziccardi P, Nappo F, Giugliano G, . Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804–809
   PubMed Web of Science ®Google Scholar
• . Adams TD, Gress RE, Smith SC, . Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–761
   PubMed Web of Science ®Google Scholar
• . Martin CL. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. Diabetes Educ. 2008;34(suppl 3):66S–72S
   Google Scholar
• . DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Macconell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943–2952
   PubMed Web of Science ®Google Scholar
• . Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94(6):1843–1852
   Google Scholar
• . Blonde L, Klein EJ, Han J, . Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436–447
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Thiriet CM, Guerci B. Reaching a clinically relevant composite endpoint of HbA1c target < 7% - no hypoglycaemia - no weight gain, with liraglutide vs other T2D therapies (abstract 593-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010
   Google Scholar
• . Courreges J-P, Thiriet CM, Abbed NS. Comparative, transversal analysis of adding metformin or glimepiride therapy to liraglutide in the treatment of type 2 diabetes (abstract 737-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010
   Google Scholar
• . Gough S, Madsbad S, Jensen K, Falahati A, Bain S. Liraglutide is associated with reduced rates of hypoglycemic events versus glimepiride when achieving target HbA1c (abstract 764-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010
   Google Scholar
• . Russell-Jones D, Sesti G, Garber A, Zinman B, Jensen K, Falahati A, Colagiuri S. Liraglutide causes reductions in body weight both in patients with and without gastrointestinal side effects (abstract 1886-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25–29, 2010
   Google Scholar
• . Matthews D, Vilsboll T, Courreges J-P, Zychma M, Falahati A, Seino Y, Bode B. Liraglutide improves beta-cell function as assessed by HOMA-B and proinsulin: insulin ratio: meta-analysis of 6 clinical trials (abstract 1513-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010
   Google Scholar